The State of Asthma Research in America
Asthma affects more than 25 million people in the United States, yet treatment responses vary dramatically from person to person. What works beautifully for one patient might barely help another, which is precisely why clinical research continues to push forward. The past few years have been particularly active. In April 2026, the FDA approved Breztri Aerosphere as the first triple-combination therapy in a single inhaler for asthma patients aged 12 and older, a decision built directly on the KALOS and LOGOS Phase III trials. That approval illustrates how clinical trials translate into real treatment options that reach pharmacy shelves.
The research landscape today spans multiple fronts. Biologic therapies targeting specific inflammatory pathways have dominated recent investigation, with drugs like tezepelumab paving the way for a wave of biosimilars and next-generation molecules. The PASSAGE study, a Phase IV real-world trial conducted across US sites, examined tezepelumab in patient populations often excluded from earlier research, including Black and African American participants, adolescents, and individuals with a smoking history. Meanwhile, newer tri-specific antibodies that simultaneously target IL-4, IL-13, and TSLP are moving through Phase II international trials with US sites actively recruiting.
Beyond biologics, researchers are exploring smarter self-management tools. A pilot randomized controlled trial at Mount Sinai, funded through NIOSH, is testing a comprehensive self-management model for World Trade Center responders with uncontrolled asthma. The American Lung Association's Airways Clinical Research Centers, a network spanning from Arizona to Vermont, continue running trials like TRIM, which investigates whether roflumilast can help patients with poorly controlled asthma and elevated BMI.
Types of Asthma Trials Currently Recruiting
Asthma studies fall into several categories, and knowing the differences helps narrow your search.
Interventional trials test a specific treatment, which could be a new medication, a device, or a behavioral program. These are broken into phases. Phase I studies focus on safety and typically involve small groups. Phase II explores dosing and early effectiveness signals. Phase III compares the investigational treatment against a placebo or standard care in larger populations. Phase IV happens after FDA approval, tracking real-world performance.
Observational studies do not involve experimental treatments. Instead, researchers collect data over time to understand disease patterns, triggers, or long-term outcomes. These tend to have fewer eligibility restrictions and may require less frequent clinic visits.
What makes the current pipeline particularly interesting is the diversity of mechanisms under investigation. Some trials target eosinophilic inflammation, the pathway behind allergic asthma. Others focus on non-type 2 inflammation, which has historically had fewer treatment options. There are also studies looking at fixed-dose inhaler combinations, digital health coaching interventions, and allergen-reduction strategies.
| Trial Type | Example Focus | Typical Duration | Participant Profile | Key Advantage | Key Consideration |
|---|
| Biologic (Phase II/III) | Anti-TSLP, anti-IL-4R | 24-52 weeks | Moderate to severe uncontrolled asthma | Access to cutting-edge mechanism | Frequent injection visits required |
| Inhaler Combination (Phase III) | Triple therapy in single device | 12-24 weeks | Broad asthma population | Convenient, familiar delivery | May require washout of current meds |
| Behavioral/Self-Management | Digital coaching, education | 3-6 months | Varies | Low medical risk | Time commitment for sessions |
| Observational | Disease progression, biomarker tracking | 6-24 months | Broad eligibility | No experimental drug exposure | No direct treatment benefit |
How to Find Trials and What to Expect
ClinicalTrials.gov remains the central registry for studies across the country. You can filter by condition ("asthma"), location (city, state, or distance from your ZIP code), and recruitment status. The American Lung Association also maintains a searchable listing of trials through its Airways Clinical Research Centers network, with sites in Arizona, Illinois, New York, North Carolina, Vermont, and other states.
When you identify a study that interests you, the first step is typically a phone screening. A research coordinator will ask about your asthma history, current medications, and general health. They are checking against the study's inclusion and exclusion criteria, which spell out exactly who qualifies. Common criteria include age range, asthma severity, lung function thresholds (often measured as FEV1 percent predicted), and exacerbation history within the past year.
If you pass the phone screen, you will attend an in-person visit where the study team explains every detail through an informed consent document. This is not just paperwork. It outlines the study's purpose, the procedures involved, potential risks, and your right to withdraw at any time. You should ask every question that comes to mind. A good research team welcomes curiosity.
During the trial itself, expect regular clinic visits for breathing tests, questionnaires, and possibly blood draws. Some studies provide daily diary cards to track symptoms and peak flow readings. The schedule varies by protocol. A biologic trial might require injections every two to four weeks, while an inhaler study could involve monthly check-ins.
Compensation practices differ across sites. Many studies offer payment for time and travel, particularly for in-person visits. The American Lung Association's COPD-OMA trial, for instance, explicitly states that compensation is available. However, amounts vary and depend on visit frequency and study duration. This is not a primary reason to join a trial, but it does help offset the logistical burden.
Real Considerations Before You Enroll
Mary, a 47-year-old teacher from Phoenix, enrolled in an asthma biologic trial after years of cycling through inhalers without consistent control. "I was nervous about the unknown," she says, "but the study team walked me through every step. The regular monitoring alone gave me more insight into my asthma than I had ever had before." Her experience highlights a benefit participants often mention: the unusually close medical attention that comes with trial participation.
That said, clinical trials are not a substitute for standard care. There is no guarantee of receiving the experimental treatment. Placebo-controlled designs mean some participants receive an inactive substance, though many studies offer an open-label extension phase where everyone eventually gets the active drug. The time commitment can also be significant. Weekly or monthly visits over a year or more require reliable transportation and scheduling flexibility.
It is also worth noting that eligibility can be narrow by design. If your asthma is well controlled on current medications, you may not qualify for studies seeking patients with uncontrolled disease. Conversely, if your lung function falls below a certain threshold, you might be excluded for safety reasons. The screening process exists to protect participants and ensure the study can answer its research question.
For those who do qualify, the potential benefits extend beyond personal health. Clinical trial participants contribute to knowledge that shapes treatment guidelines for millions of other patients. That legacy matters to many who choose to participate.
If you are considering a trial, start by having an honest conversation with your pulmonologist or allergist. They can help assess whether a research study aligns with your treatment goals and may know of local studies actively recruiting. Then explore ClinicalTrials.gov or the American Lung Association's research pages to see what is available near you. Read the eligibility criteria carefully. When you contact a study site, bring a list of your current medications and a summary of your asthma history. The more prepared you are, the smoother the screening process will be.
研究の知恵